secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001193125-22-307300
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios adopts performance-based cash bonus for CMO tied to ENERGIZE trial milestone
--------------------------------------------------------------------------------

- Dr. Sarah Gheuens, CMO and Head of R&D, eligible for up to 1.25x her 2022 target bonus ($309,375) if ENERGIZE trial milestone achieved by April 2024.
- If milestone achieved before April 2024, bonus increases to 1.2x the baseline amount, totaling $371,250.
- Bonus payment contingent on Dr. Gheuens remaining employed at time of milestone achievement.
- CEO, CFO, and Chief Commercial Officer are not eligible for this bonus plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522307300/0001193125-22-307300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522307300/d428911d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-307300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer